Gilead Announces 11-Year Plan to Donate PrEP Medication to 200,000 Per Year

May 09, 2019 | Kim Rodgers

On May 9, 2019, Health and Human Services Secretary Alex M. Azar II announced that, as a result of discussions between the Trump Administration and Gilead Sciences, Inc., the pharmaceutical company has agreed to donate pre-exposure prophylaxis (PrEP) medication for up to 200,000 individuals each year for up to 11 years. PrEP is used to reduce the risk of HIV infection in individuals who are at higher risk for HIV. It has been shown to reduce the risk of new infection by up to 97 percent when taken consistently.

The agreement between the U.S. Department of Health and Human Services and Gilead will last until at least December 31, 2025 and possibly through December 31, 2030, and will provide medication to treat individuals who are at risk for HIV and who are uninsured. This donation will deliver Gilead’s PrEP medication Truvada, which currently carries a list price of more than $20,000 per patient per year, to up to 200,000 people per year, including in the states and counties identified as priority areas in the Trump Administration plan to end the HIV epidemic in America.

Gilead will donate Truvada until its second-generation HIV preventative medication, Descovy, becomes available. At that time, Gilead will donate Descovy. The agreement would end after 11 years, or when a generic version of Descovy becomes commercially available, whichever comes first. The government has agreed to cover costs associated with distributing the drugs.

Secretary Azar issued the following statement regarding the finalized agreement:

“Securing this commitment is a major step in the Trump Administration’s efforts to use the prevention and treatment tools we have to end the HIV epidemic in America by 2030. Under President Trump’s leadership, HHS worked with Gilead to secure preventative medication for individuals who might otherwise not be able to access or afford this important treatment. The majority of Americans who are at risk and who could protect themselves with PrEP are still not receiving the medication. This agreement will help close that gap substantially and deliver on President Trump’s promise to end the HIV epidemic in America.”

Additional Background:

In his State of the Union Address on February 5, 2019, President Donald J. Trump announced his Administration’s goal to end the HIV epidemic in the United States within 10 years. To achieve this goal and address the ongoing public health crisis of HIV, the initiative Ending the HIV Epidemic: A Plan for America will leverage the powerful data and tools now available to reduce new HIV infections in the United States by 75 percent in five years and by 90 percent by 2030. In his FY 2020 Budget, President Trump proposed historic new funding dedicated specifically to this initiative.

To read the HHS’s statement on FY2020 Budget proposal for ending the HIV epidemic In America, please visit: https://www.hhs.gov/about/news/2019/03/11/statement-on-fy2020-budget-proposal-for-ending-the-hiv-epidemic-in-america.html

For more information, please visit:www.hiv.gov


637020799465370000

About Kim Rodgers

Kim Rodgers is the Communications Manager at NACCHO.

More posts by Kim Rodgers

0 Comments

Related Posts

Cdc badge small
  • Tools & Resources

CDC Report: Temporary Reassignment of Personnel Requests...

CDC recently updated its flexibilities guidance for recipients and applicants...

Jul 09, 2020 | Kim Rodgers

CDC Report: Temporary Reassignment of Personnel Requests...

Jennifer kertanis headshot 24152456360
  • Opportunity

Top Moments From Day Two at NACCHO 360

Welcome to the final day of NACCHO 360! Yesterday NACCHO Chief Executive...

Jul 09, 2020 | Taylarr Lopez

Top Moments From Day Two at NACCHO 360

COVID VC Screenshot
  • COVID-19
  • Tools & Resources
  • Emergency Response
  • Infectious Disease

NACCHO’s COVID-19 Virtual Community Now Available to All...

NACCHO has opened our COVID-19 Virtual Community to all local health department...

Jul 08, 2020 | Kim Rodgers

NACCHO’s COVID-19 Virtual Community Now Available to All...

Sync2020 logos horizontal 1024x304
  • HIV, STI, & Viral Hepatitis

Scholarships Available: SYNChronicity 2020 Conference –...

SYNC 2020, the National Conference for HIV, HCV, STI and LGBTQ Health, is...

Jul 08, 2020 | Julia Zigman

Scholarships Available: SYNChronicity 2020 Conference –...

  • COVID-19
  • HIV, STI, & Viral Hepatitis
  • Research & Reports

Kaiser Family Foundation: Reduction in Sexual and...

The Kaiser Family Foundation released a new issue brief, Potential Impacts of...

Jul 08, 2020 | Julia Zigman

Kaiser Family Foundation: Reduction in Sexual and...

2000px US CDC logo
  • HIV, STI, & Viral Hepatitis

New Recommendations for Hepatitis Vaccination

CDC has released new recommendations for hepatitis A virus (HAV) vaccination,...

Jul 08, 2020 | Julia Zigman

New Recommendations for Hepatitis Vaccination

TAG Logo
  • HIV, STI, & Viral Hepatitis
  • Research & Reports

Treatment Action Group 2020 Pipeline Report Now Available

Treatment Action Group (TAG) recently published their 2020 Pipeline Report, an...

Jul 08, 2020 | Julia Zigman

Treatment Action Group 2020 Pipeline Report Now Available

Pr EP injectable
  • HIV, STI, & Viral Hepatitis
  • Research & Reports

New Study: Injectable PrEP is Safe and Highly Effective

New data further shows an injectable antiretroviral for HIV pre-exposure...

Jul 08, 2020 | Julia Zigman

New Study: Injectable PrEP is Safe and Highly Effective

MMWR
  • HIV, STI, & Viral Hepatitis
  • Research & Reports

HIV Testing Trends at Visits to Physician Offices,...

A recent report from CDC shows low rates of HIV testing in physician offices,...

Jul 08, 2020 | Julia Zigman

HIV Testing Trends at Visits to Physician Offices,...

Back to Top